

# Injectable Cytotoxic Drugs Market: Future Demand and Top Key Players Analysis | 2029

*The Business Research Company's  
Injectable Cytotoxic Drugs Global Market  
Report 2025 – Market Size, Trends, And  
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, August 21, 2025

/EINPresswire.com/ -- What Is The  
Expected Cagr For The [Injectable  
Cytotoxic Drugs Market](#) Through 2025?

The market size for injectable cytotoxic drugs has observed sturdy growth in the recent past. The market valuation is anticipated to rise from \$18.16 billion in 2024 to \$19.41 billion in 2025 with a compound annual growth rate (CAGR) of 6.9%. The growth in the past period can be accredited



Get 30% Off All Global  
Market Reports With Code  
ONLINE30 – Stay Ahead Of  
Trade Shifts,  
Macroeconomic Trends, And  
Industry Disruptors

”

*The Business Research  
Company*

to the growing acceptance of combination chemotherapy treatments, increased spending in healthcare, an uptick in the number of specialized cancer clinics and treatment establishments, an increasing number of approved generic injectable cytotoxic drugs, and growing consciousness about early cancer detection.

The market for injectable cytotoxic drugs is projected to experience robust expansion in the coming years, with a value propelling to \$25.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth is associated with the rising acceptance of biosimilar

cytotoxic medications, an increased emphasis on outpatient and home-based chemotherapy, an expanding portfolio of injectable cancer drugs, a rising prevalence of cancer, and growing demand for economical cancer therapies. The forecast period will see key trends including advancements in injectable drug delivery technologies, enhanced formulation methods to minimize toxicity, innovation in the development of antibody-drug conjugates, the incorporation of AI in cancer drug discovery, and partnerships among pharmaceutical corporations.

Download a free sample of the injectable cytotoxic drugs market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=25795&type=smp>

The Business  
Research Company

The Business Research Company



### What Are The Key Factors Driving Growth In The Injectable Cytotoxic Drugs Market?

The growth of the injectable cytotoxic drugs market is anticipated to be driven by the escalating prevalence of rheumatoid arthritis. Rheumatoid arthritis, a chronic autoimmune disease, is characterized by continuous joint inflammation, pain, and eventual joint deterioration. The surge in rheumatoid arthritis cases can be largely attributed to an aging population, as older age can amplify the chances of genetic aberrations and immune system malfunctions, all of which can trigger this disease. Injectable cytotoxic drugs can manage rheumatoid arthritis by targeting cells that divide rapidly and repressing exaggerated immune responses, thus slowing the progress of the disease and diminishing its symptoms. For example, data released by the Australian Institute of Health and Welfare in June 2024 revealed that rheumatoid arthritis was the cause of 1,322 deaths, translating to 5.1 deaths per 100,000 individuals, and constituted 0.7% of all deaths in 2022. The disease also accounted for 2.0% of the overall disease burden, representing 16% of the total burden from all musculoskeletal conditions in 2023. Therefore, the mounting prevalence of rheumatoid arthritis is fueling the expansion of the injectable cytotoxic drugs market.

### What Are The Top Players Operating In The Injectable Cytotoxic Drugs Market?

Major players in the Injectable Cytotoxic Drugs Global Market Report 2025 include:

- Pfizer Inc.
- F. Hoffmann–La Roche Ltd.
- Sanofi S.A.
- Bristol–Myers Squibb
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Merck KGaA
- Baxter International Inc.
- Fresenius Kabi AG

### What Are The Major Trends That Will Shape The Injectable Cytotoxic Drugs Market In The Future?

Major players in the injectable cytotoxic drugs market are concentrating their efforts on securing regulatory approvals to broaden their product offerings and expedite their entry into the market. Regulatory approvals are the official permissions issued by health authorities, affirming that a certain drug has passed the necessary safety, efficacy, and quality standards prior to marketing and prescription. For instance, in March 2024, Astellas Pharma Inc., a pharmaceutical firm based in Japan, gained the approval for VYLOY (zolbetuximab) from Japan's Ministry of Health, Labour, and Welfare (MHLW). This was for the treatment of CLDN18.2-positive, non-removable, advanced or recurrent gastric cancer. The approval came on the back of Phase III clinical trials (SPOTLIGHT and GLOW) that showed VYLOY, when converged with chemotherapy, significantly increased both progression-free and overall survival. The identification of eligible patients for this course of treatment is achieved through a diagnostic test which detects CLDN18.2 expression in tumor

cells. This addresses a crucial gap in gastric cancer treatment—an affliction often diagnosed late and having a global reputation for poor prognosis.

## Comprehensive Segment-Wise Insights Into The Injectable Cytotoxic Drugs Market

The injectable cytotoxic drugs market covered in this report is segmented –

- 1) By Drug Type: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Platinum-Based Compounds, Cytotoxic Antibiotics, Other Drug Types
- 2) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous (SC)
- 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Drug Stores
- 4) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Lymphoma, Leukemia, Other Applications
- 5) By End-User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research And Academic Institutes

### Subsegments:

- 1) By Alkylating Agents: Cyclophosphamide, Isocyanide, Melphalan, Busulfan
- 2) By Antimetabolites: Methotrexate, 5-Fluorouracil (5-FU), Cytarabine, Gemcitabine
- 3) By Plant Alkaloids: Vincristine, Vinblastine, Paclitaxel, Docetaxel
- 4) By Antitumor Antibiotics: Doxorubicin, Daunorubicin, Epirubicin, Bleomycin
- 5) By Platinum-Based Compounds: Cisplatin, Carboplatin, Oxaliplatin
- 6) By Cytotoxic Antibiotics: Mitomycin, Actinomycin D, Plicamycin
- 7) By Other Drug Types: Irinotecan, Etoposide, Denibulin, Trastuzumab Emtansine (ADC), Lutetium-177 Dotatate

View the full injectable cytotoxic drugs market report:

<https://www.thebusinessresearchcompany.com/report/injectable-cytotoxic-drugs-global-market-report>

### Global Injectable Cytotoxic Drugs Market - Regional Insights

In 2024, North America held the biggest share in the global injectable cytotoxic drugs market. However, Asia-Pacific is predicted to experience the most substantial growth in the forecast period. The report on the injectable cytotoxic drugs market includes regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the [Global Injectable Cytotoxic Drugs Market 2025](#), By [The Business Research Company](#)

### Respiratory Inhaler Devices Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/respiratory-inhaler-devices-global-market-report>

## Respiratory Devices And Equipment Therapeutic Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report>

## Smart Inhalers Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/smart-inhalers-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: [saumyas@tbrc.info](mailto:saumyas@tbrc.info)

The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com)

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/841801832>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.